Ngoc Pham, MD
Radiation Oncology · Houston, TXNPI 1912342908
Payments from drug & device makers
Across 69 payments — averaging $26.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tactile Systems Technology Inc$457
- AstraZeneca$352
- Gilead$222
- Siemens Medical Solutions USA, Inc.$163
- Tempus AI, Inc$151
- Blue Earth Diagnostics$102
- plus $349 from 12 others
What the payments were for
- Food & beverage$1,796100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tactile Systems Technology Inc | 30 | $457 |
| AstraZeneca | 6 | $352 |
| Gilead | 2 | $222 |
| Siemens Medical Solutions USA, Inc. | 2 | $163 |
| Tempus AI, Inc | 8 | $151 |
| Blue Earth Diagnostics | 3 | $102 |
| Novartis | 3 | $62 |
| Progenics Pharmaceuticals, Inc. | 2 | $56 |
| Sumitomo Pharma America, Inc. | 2 | $45 |
| Novocure Inc. | 2 | $43 |
| Agios Pharmaceuticals, Inc. | 2 | $26 |
| Bayer | 1 | $21 |
| Innovation Technologies Inc | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Amgen | 1 | $19 |
| Pfizer | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Cashflow Solutions, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,796 in reported general payments places this provider in the 65th percentile of 418 radiation oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 59 | $1,656 |
| Sucralfate | 24 | $1,310 |
| Tamsulosin Hcl | 42 | $672 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 25 | $486 |
| Oxybutynin Chloride ErOxybutynin Chloride | 15 | $427 |
| Finasteride | 30 | $389 |
| Lidocaine Hcl ViscousLidocaine Hcl | 15 | $295 |
| Omeprazole | 19 | $129 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Houston
- Daniel GomezHouston$8.7M
- Chad TangHouston$7.7M
- James WelshHouston$5.1M
- Caroline ChungHouston$3.7M
- Karen HoffmanHouston$2.6M
- Clifton FullerHouston$1.6M
- Steven LinHouston$1.5M
- Chenyang WangHouston$1.4M
- Joe ChangHouston$1.2M
- Lilie LinHouston$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.